NCT06720714

A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

An Open-Label, Single-Dose Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to assess the concentration of rozanolixizumab in mature breast milk of healthy study participants following administration of a single dose of rozanolixizumab

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Rozanolixizumab	Dose formulation: Solution for injection Route of administration: Subcutaneous infusion

Timeline

• Start date: 2024-12-03
• Primary completion: 2025-05-12
• Completion: 2025-05-12
• First posted: 2024-12-06
• Last updated: 2025-05-20

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study